Jun 03,2022

Diabeloop, SOOIL partner on automated insulin delivery technology

Paris-based Diabeloop, which develops therapeutic artificial intelligence (AI) applied to insulin delivery, and SOOIL will pursue and expand upon technical integration between their platforms, building on cooperation that was initiated in February 2020. The partnership will pursue the technical integration of the Dana-i ACE pump within the DBLG1 system as the entry point of the collaboration.

COLLABORATION PARTNERSHIP

#connected device

#insulin pump

#closed loop

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

One Drop Study Signals Significant Growing Interest in Continuous Glucose Monitors (CGMs) Among People with Type 2 Diabetes

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association on attitudes and adoption of continuous glucose monitors (CGM) among people with type 2 diabetes (T2D).

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

One Drop’s Digital Solution Helps People with Type 2 Diabetes Who Are at Greater Risk of Health Inequities

One Drop, a leader in precision health solutions for people living with diabetes and other chronic conditions, presented new research at the 82nd Scientific Sessions of the American Diabetes Association (ADA 2022) linking cumulative risk of health inequities to platform engagement and attitudes towards One Drop among people with type 2 diabetes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

Health Care Professionals’ Perspectives on Use of Diabetes Technologies for Managing Visually Impaired Patients With Diabetes

The study aimed to identify providers’ preferences and challenges to prescribing diabetes technologies for visually impaired patients.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 04,2022

Neural Networks With Gated Recurrent Units Reduce Glucose Forecasting Error due to Changes in Sensor Location

Recently, neural networks (NNs) have become a common method for forecasting glucose values using data from CGMs. One method of forecasting glucose values is a time-delay feedforward (FF) NN, but a change in the CGM location on a participant can increase forecast error in a FF NN.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 05,2022

LATE-BREAKING DATA DEMONSTRATE ABBOTT'S FREESTYLE LIBRE® 3 SYSTEM IS MOST ACCURATE 14-DAY CONTINUOUS GLUCOSE MONITOR

Abbott (NYSE: ABT) today announced late-breaking clinical data that demonstrate the FreeStyle Libre® 3 system has an overall mean absolute relative difference (MARD) of 7.9%,1 making it the first and only 14-day continuous glucose monitoring (CGM) system to achieve a sub-8% overall MARD.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Jun 05,2022

Bigfoot Unity® Demonstrates Strong Glycemic Control Among People with Type 2 Diabetes in Real-World Retrospective Analysis

Bigfoot Biomedical, a mission-driven company dedicated to supporting better health outcomes for people with insulin-requiring diabetes, presented real-world data from its late-breaking abstract presented at the American Diabetes Association 82nd Annual Scientific Sessions. Data from the real-world retrospective analysis suggests that, for people on multiple daily injections (MDI) of insulin, using the Bigfoot Unity System has the potential for rapid and durable improvement in glycemic control.

CLINICAL STUDY

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Diabetes Reversal Leader Virta Health Showcases Transformative, Long-Lasting Cardiometabolic Health Improvements for Veteran Patients

Today, Virta Health, the type 2 diabetes reversal leader, announced two-year patient outcomes from its multi-year partnership with the Department of Veterans Affairs (VA). The results, presented at the American Diabetes Association 82nd Scientific Sessions, highlight broad metabolic health improvements for Veteran patients, including long-term blood sugar reduction, clinically-significant weight loss, and medication deprescription.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

Virta Health Highlights Lasting, Transformative Health Improvements In 5-Year Diabetes Reversal Study

Virta Health, the leader in type 2 diabetes reversal, revealed preliminary five-year results from its landmark clinical trial at the American Diabetes Association 82nd Scientific Sessions. Presenting four unique abstracts, Virta highlighted myriad, lasting health improvements for people with type 2 diabetes and prediabetes, including blood sugar control, clinically-significant weight loss, reduced inflammation, and improvements in other markers of cardiometabolic health.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jun 06,2022

ieso Announces Results Showing Novel Form of Online Cognitive Behavioral Therapy Improves Patient Outcomes in Type 2 Diabetes

Study results presented at the 2022 American Diabetes Association (ADA) Annual Conference, report that integrated mental healthcare in diabetes patients can improve mental health outcomes, patient engagement with self-management of diabetes, diabetes distress, and quality of life.

CLINICAL STUDY

#dtx

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES